Skip to main content
    B

    BeOne Medicines AG (ONC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $411.29
    -5.25 (-1.26%)

    Market Cap: $47.58B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    BeOne Medicines AG (ONC) P/E Ratio & Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    BeOne Medicines AG (ONC) trades at 50.0x trailing earnings and 18.7x sales. Its P/S of 18.7x is below its 5-year median of 52.1x. Its forward P/E is 36.5x. The median P/E across 7 similar companies is 30.0x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 37.0% higher over the next year. Its free cash flow yield is 1.3%.

    MultipleValue
    P/E (trailing)50.0x
    Forward P/E36.5x
    Price to sales18.7x
    Price to book8.3x
    EV/EBITDA73.2x
    Price to FCF80.0x
    EV/FCF72.2x
    PEG0.7
    FCF yield1.3%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 83.0% below 110.3x and its P/B is 79.8% below 41.0x.

    MultipleCurrent5-year median10-year median
    P/S18.7x52.1x110.3x
    P/B8.3x40.1x41.0x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 103 to 120 months (10-year).

    Valuation History

    Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 36.7x in 2024 to 950.4x in 2016.

    Year endPriceP/SP/B
    2025$303.8145.8x55.3x
    2024$184.7136.7x43.0x
    2023$180.3655.2x37.7x
    2022$219.94108.6x35.9x
    2021$270.93142.0x26.7x
    2020$258.39483.0x39.6x
    2019$165.76159.6x72.8x
    2018$140.26264.0x32.7x
    2017$97.72N/A42.3x
    2016$30.36950.4x23.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    P/E history is shown only for companies that report in US dollars.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ONC

    What is ONC's forward P/E ratio?

    BeOne Medicines AG has a forward P/E ratio of 36.5x.

    Is ONC stock overvalued?

    GNG's valuation label for ONC is Overvalued. Its P/E of 50.0x compares with a median of 30.0x across 7 similar companies.

    What is ONC's price to sales ratio?

    BeOne Medicines AG has a price to sales ratio of 18.7x.

    What is ONC's PEG ratio?

    BeOne Medicines AG has a PEG ratio of 0.7.